Rigel Pharma Shares Up 14% In Tuesday's Premarket, Continuing Run From Mon.; Shares Rallied 32+% On Mon. Following News The FDA Indicated It Will Not Hold An AdCom Meeting For Fostamatinib
Paul Quintaro